A pharmaceutical composition for cancer treatment, comprising an Axl inhibitor and an anticancer drug (for example, a cytotoxic anticancer drug, a molecular target drug, an anti-CTLA-4 antibody, and the like), wherein the Axl inhibitor is a compound represented by the general formula (I):(wherein all of the symbols have the same meanings as set forth in the specification), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug thereof, and which exhibits a strong antitumor effect, and therefore is useful for treatment of blood cancer and/or solid cancer.
